Earnings ·
Cytek Biosciences reported second quarter 2026 financial results with total revenue of $48.1 million, a 6% increase…
CTKBCytek Biosciences, Inc.
Cytek Biosciences reported second quarter 2026 financial results with total revenue of $48.1 million, a 6% increase year-over-year. The company updated its full-year 2026 revenue guidance to $207 million–$212 million, raising the midpoint by $1 million. GAAP net loss widened to $12.2 million from $5.6 million in the prior year period, driven by a $1.6 million write-off of an investment and increased litigation-related expenses within general and administrative costs. Operating expenses rose 15% to $39.7 million. The company launched the Cytek Borealis flow cytometer and expanded its installed base to 3,933 instruments. Cytek Biosciences operates in the life sciences industry, providing cell analysis solutions including flow cytometers, reagents, and software.